José Antonio Oliveras Torres

Dr. José Antonio Oliveras Torres

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2025 in Cancer Research
Verified
Journal Article
Closed access
MMMarco Matejcic
Marco Matejcic
JTJamie K. Teer
Jamie K. Teer
HHHannah J. Hoehn
Hannah J. Hoehn
DDDiana B. Diaz
Diana B. Diaz
KSKritika Shankar
Kritika Shankar
SSStephanie L. Schmit
Stephanie L. Schmit
Admixed populations, including the Hispanic/Latino/a community, are underrepresented in cancer genetic/genomic studies. Leveraging the Latino Colorectal Cancer Consortium (LC3) and other existing datasets, we analyzed whole-exome sequencing data on tumor/normal pairs from 718 individuals with colorectal cancer to map somatic mutational features by ethnicity and genetic similarity. Global proportions of African, Asian, European, and Native American genetic ancestries were estimated using ADMIXTURE. Associations between these proportions and somatic mutational features were examined using logistic regression. APC, TP53, and KRAS were the top three mutated genes across all participants and in the subset of Latino individuals in LC3. In analyses examining recurrently mutated genes, tumors from patients of Latino ethnicity had fewer KRAS and PIK3CA mutations compared with tumors from non-Latino patients. Genetic ancestry overall was associated with CDC27 mutation status, and African genetic ancestry was associated with SMAD2 mutation status. In exome-wide analyses, African genetic ancestry was significantly associated with higher odds of mutation in KNCN and TMEM184B. Native American genetic ancestry was associated with a lower frequency of microsatellite instability–high tumors. The SBS11 mutational signature was associated with Native American genetic ancestry as well as Latino ethnicity. In an independent replication dataset, MSK-IMPACT, estimates of association were largely consistent in direction but nonsignificant. A meta-analysis of LC3 and MSK-IMPACT showed that African genetic ancestry was significantly associated with KRAS mutation status and MSI status. This work facilitates precision medicine initiatives by providing insights into the contribution of genetic ancestry to molecular features of colorectal tumors. Significance: Analysis of tumors from various populations can broadly characterize genomic landscapes and enhance precision medicine strategies.

16 January 2025 in Cancers
Verified
Journal Article
Open access
PDF file
JMJaime Matta
Jaime Matta
COCarmen Ortiz
Carmen Ortiz
JEJarline Encarnacion
Jarline Encarnacion
SCStephanie Torres Caraballo
Stephanie Torres Caraballo
JTJosé Antonio Oliveras Torres
José Antonio Oliveras Torres
GRGilberto Ruiz-Deyá
Gilberto Ruiz-Deyá
Background: Prostate cancer (PCa) accounts for 22% of the new cases diagnosed in Hispanic/Latino (H/L) men in the US. PCa has the highest incidence (38.3%) and mortality (16.4%) among all types of cancer diagnosed in Puerto Rico. We previously showed that PCa patients (n = 41) have a significant reduction of 59% in their levels of DNA repair capacity (DRC) when compared to controls (n = 14). This study aimed to evaluate DRC levels through the nucleotide excision repair (NER) pathway for the first time in 16 Puerto Rican H/L men with metastatic castration-resistant PCa (mCRPCa) while establishing comparisons with controls and PCa patients with indolent and aggressive disease. Methods: Blood samples and clinicopathological data from PCa cases (n = 71) and controls (n = 25) were evaluated. PCa cases were stratified into mCRPCa (n = 16), aggressive (n = 31), and indolent (n = 24). DRC levels through NER were measured in lymphocytes with the CometChip assay. The stratification by Gleason score (GS) was GS6 (n = 7), GS7 (n = 23), GS ≥ 8 (n = 20), and mCRPCa patients (n = 16). Results: Significant statistical differences were found when comparing the DRC values of the controls with any other of the four PCa patient groups. mCRPCa patients had the lowest mean DRC level of all four patient groups studied. The mean DRC level of mCRPCa patients was 6.65%, and compared to the controls, this represented a statistically significant reduction of 62% (p < 0.0001). Further analysis was performed to evaluate the contributions of age, anthropometric measurements, and prostate-specific antigen (PSA) levels to the DRC. Kaplan–Meier curves of mCRPCa revealed that survival probability decreased by approximately 50% by 30 months. This pilot study uses a blood-based phenotypic assay to present the first report of mCRPCa in Puerto Rican men and at a global level of DRC levels of mCRPCa patients. Conclusions: This study evaluated DRC levels through the NER pathway for the first time in 16 Puerto Rican H/L men with mCRPCa. Significant differences in DRC values were found between the controls and the three PCa patient groups. Kaplan–Meier curves revealed that survival probability decreased by approximately 50% by 30 months, and only 20% of the cohort was alive at 50 months, confirming the lethality of mCRPCa in this H/L population. This pilot study represents the first report of metastatic PCa in Puerto Rican men at a global level of DRC levels of mCRPCa patients using a blood-based phenotypic assay.

20 March 2025 in JNCI Cancer Spectrum
Verified
Journal Article
Open access
SSStephanie L Schmit
Stephanie L Schmit
NLNicole C Loroña
Nicole C Loroña
DSDaniel Sobieski
Daniel Sobieski
MMMarco Matejcic
Marco Matejcic
NNNathalie T Nguyen
Nathalie T Nguyen
JFJane C Figueiredo
Jane C Figueiredo
Background: Addressing critical gaps in precision medicine initiatives in colorectal cancer (CRC) requires building larger collaborative studies. Methods: The Latino Colorectal Cancer Consortium (LC3) is a resource that harmonizes data collected in observational studies with data from individuals who identify as Hispanic/Latino with a diagnosis of primary colorectal adenocarcinoma. Data collected includes demographics, medical history, family history, and lifestyle risk factors from patient-completed surveys. Vital status, cause of death, treatment, and clinicopathological characteristics were obtained through medical chart abstraction, pathology reports, and/or linkage to state cancer registries. Blood, saliva, or normal colonic tissues were used to extract and genotype germline DNA. Tumor tissue (snap frozen or formalin-fixed paraffin-embedded) was evaluated by pathologists for diagnosis, tissue content, tumor cellularity, necrosis, immune infiltration, and additional histopathological characteristics. A centralized database with a virtual tumor repository was created to facilitate collaborative research. Results: As of April 2024, LC3 assembled data from 2210 patients (diagnosed 1994 to 2023). The mean age at diagnosis was 57 (range: 19–93) years; 54.3% of participants were male, and 62.0% had been diagnosed with colon cancer. Surveys were completed by 1722 (77.8%) participants. Ongoing multi-omics profiling on up to 600 patients include: genome-wide germline genotyping, paired tumor/normal whole exome sequencing, bulk RNA-seq, T cell receptor immunosequencing, and multiplex immunofluorescence. Conclusions: This consortium fills an important gap in research infrastructure in CRC as well as improving precision medicine initiatives for all individuals.

1 May 2025 in Cancer Research Communications
Verified
Journal Article
Open access
ALAbigail E. Lantz
Abigail E. Lantz
EGEdna R. Gordián
Edna R. Gordián
MRMarilin Rosa
Marilin Rosa
MRMarileana Rodríguez-Ruíz
Marileana Rodríguez-Ruíz
JJJoseph O. Johnson
Joseph O. Johnson
WCWilliam D. Cress
William D. Cress
Breast cancer is a leading cause of cancer-related mortality among women worldwide and is known to have higher mortality among women with African ancestry. Herein, we describe the creation and characterization of a multiethnic breast cancer tissue microarray (ME-BrTMA) representing tumors from non-Hispanic White (n = 41), non-Hispanic Black (NHB; n = 45), and Hispanic patients from Puerto Rico (n = 36) and Florida (n = 52). This ME-BrTMA comprises five blocks with a total of 610 cores: 371 breast cancer tumor cores, 93 breast stromal cores, 96 normal breast tissue cores, 30 non–breast cancer tumor cores, and 20 cores representing normal tissues. Initial characterization of the ME-BrTMA includes standard IHC staining of well-characterized clinical biomarkers, including the estrogen hormone receptors and progesterone hormone receptors, HER2, and Ki-67, interpreted by the coauthoring pathologist (Marilin Rosa). The IHC results indicated good but imperfect alignment with clinical diagnoses. Cores from breast cancer tumors from the NHB cohort most frequently scored negative for estrogen receptor (63%, P < 0.005) and progesterone receptor (80%, P < 0.005) and most frequently have high expression of the Ki-67 proliferation marker (38%, P < 0.05). Prediction Analysis of Microarray 50 (PAM50) analysis using RNA from secondary patient blocks showed that the NHB group also most frequently scored in the basal-like category (61%, P < 0.05). Taken together, the initial characterization of the ME-BrTMA suggests that it may serve as a representative resource to understand the underlying biology of breast cancer and its relationship to patient outcomes. Significance: The ME-BrTMA described herein provides a resource that may serve as a tool to understand the underlying biology of breast cancer.


15 May 2025
Verified
Other
Open access
MMMarco Matejcic
Marco Matejcic
JTJamie K. Teer
Jamie K. Teer
HHHannah J. Hoehn
Hannah J. Hoehn
DDDiana B. Diaz
Diana B. Diaz
KSKritika Shankar
Kritika Shankar
SSStephanie L. Schmit
Stephanie L. Schmit
Supplementary Table 15 shows association between tumor mutational signatures and ethnicity in 597 colorectal cancer patients